Evidence map›Paper›PMID 41413210›Full record

ArticleScientific reports2025

Virus-derived serpin reduces immuno-coagulopathic damage in murine colitis by targeting the urokinase-type plasminogen activator receptor (uPAR) and complement.

Alexandra R Lucas, Henna Monder, Junior Enow, Cheyanne Woodrow, Laurel Spaccarelli, Aman Garg, Jessika Schlievert, Nora Elmadbouly, Aashika Dupati, Emily Aliskevich and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Alexandra R LucasCenter for Personalized Diagnostics, Biodesign Institute, Arizona State University, 727 E Tyler Street, Tempe, AZ, 85287, USA. alexluc1@asu.edu.
Henna MonderCenter for Personalized Diagnostics, Biodesign Institute, Arizona State University, 727 E Tyler Street, Tempe, AZ, 85287, USA.
Junior EnowCenter for Personalized Diagnostics, Biodesign Institute, Arizona State University, 727 E Tyler Street, Tempe, AZ, 85287, USA.
Cheyanne WoodrowCenter for Personalized Diagnostics, Biodesign Institute, Arizona State University, 727 E Tyler Street, Tempe, AZ, 85287, USA.
Laurel SpaccarelliCenter for Personalized Diagnostics, Biodesign Institute, Arizona State University, 727 E Tyler Street, Tempe, AZ, 85287, USA.
Aman GargCenter for Personalized Diagnostics, Biodesign Institute, Arizona State University, 727 E Tyler Street, Tempe, AZ, 85287, USA.
Jessika SchlievertCenter for Immunotherapy Vaccines and Virotherapy, Biodesign Institute, Arizona State University, 727 E Tyler Street, Tempe, AZ, 85287, USA.
Nora ElmadboulyCenter for Personalized Diagnostics, Biodesign Institute, Arizona State University, 727 E Tyler Street, Tempe, AZ, 85287, USA.
Aashika DupatiCenter for Personalized Diagnostics, Biodesign Institute, Arizona State University, 727 E Tyler Street, Tempe, AZ, 85287, USA.
Emily AliskevichCenter for Personalized Diagnostics, Biodesign Institute, Arizona State University, 727 E Tyler Street, Tempe, AZ, 85287, USA.
Rohan SajuCenter for Personalized Diagnostics, Biodesign Institute, Arizona State University, 727 E Tyler Street, Tempe, AZ, 85287, USA.
Jacqueline KilbourneDepartment of Animal Care and Technologies, Biodesign Institute, Arizona State University, 550 Orange Street, Tempe, AZ, 85287, USA.
Kenneth LoweDepartment of Animal Care and Technologies, Biodesign Institute, Arizona State University, 550 Orange Street, Tempe, AZ, 85287, USA.
Mostafa HamadaCenter for Personalized Diagnostics, Biodesign Institute, Arizona State University, 727 E Tyler Street, Tempe, AZ, 85287, USA.
Aubrey PintericCenter for Personalized Diagnostics, Biodesign Institute, Arizona State University, 727 E Tyler Street, Tempe, AZ, 85287, USA.
Isabela R ZanettiCenter for Personalized Diagnostics, Biodesign Institute, Arizona State University, 727 E Tyler Street, Tempe, AZ, 85287, USA.
Ritvik Srivant SatyanarayananCenter for Personalized Diagnostics, Biodesign Institute, Arizona State University, 727 E Tyler Street, Tempe, AZ, 85287, USA.
Savanah GisrielDepartment of Pathology, University of Wisconsin, 1685 Highland Avenue, Madison Wisconsin, USA.
Esther Borges FlorsheimCenter for Immunotherapy Vaccines and Virotherapy, Biodesign Institute, Arizona State University, 727 E Tyler Street, Tempe, AZ, 85287, USA.
Masmudur RahmanCenter for Personalized Diagnostics, Biodesign Institute, Arizona State University, 727 E Tyler Street, Tempe, AZ, 85287, USA.
James IrvingUniversity College London, London, UK.
Grant McFaddenCenter for Immunotherapy Vaccines and Virotherapy, Biodesign Institute, Arizona State University, 727 E Tyler Street, Tempe, AZ, 85287, USA.
Wei KongCenter for Immunotherapy Vaccines and Virotherapy, Biodesign Institute, Arizona State University, 727 E Tyler Street, Tempe, AZ, 85287, USA.
Liqiang ZhangCenter for Personalized Diagnostics, Biodesign Institute, Arizona State University, 727 E Tyler Street, Tempe, AZ, 85287, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A virus-derived serpin, Serp-1, has proven efficacy in treating inflammatory and coagulation disorders in preclinical and clinical studies. Serp-1 evolved over millions of years to block host immune responses, targeting serine proteases in immune and coagulation pathways. Treatment with PEGylated Serp-1 (PEGSerp-1) protein reduced lung injury in both lupus lung hemorrhage and SARS-CoV-2 models. Here, PEGSerp-1 effects on immune-coagulopathic responses is examined in a mouse colitis model. Inflammatory bowel disease (IBD) is associated with life-threatening complications with severe inflammation, bleeding, vasculitis, cancer and toxic megacolon. Serine protease cascades activate coagulation and complement pathways throughout the human body and are regulated by inhibitors, termed serpins, that can reduce gut inflammation. Prophylactic PEGSerp-1 significantly improved survival in severe 5% Dextran sodium sulfate (DSS) colitis, reducing inflammation and crypt damage. Colon damage and inflammation were also reduced after either acute colitis induced by 5% DSS or repeat 2% DSS induced colitis. PEGSerp-1 reduced inflammatory M1 macrophage invasion, urokinase-type plasminogen activator receptor (uPAR), fibrinogen and complement on immunohistochemical analysis. PEGSerp-1 reduced uPAR expression in human macrophage, but not colon cells. Here we report analysis of PEGSerp-1 as a tissue and macrophage targeting therapeutic for colitis, reducing immune and coagulation induced damage in the colon.

Indexed as

ColitisComplement System ProteinsReceptors, Urokinase Plasminogen ActivatorSerpinsAnimalsColonDextran SulfateDisease Models, AnimalFemaleHumansMiceMice, Inbred C57BLComplement System ProteinsDextran SulfateReceptors, Urokinase Plasminogen ActivatorSerpins

Identifiers

PMID41413210
PMCPMC12824185

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.